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, and Daryll M. Baker, PhD, FRCS 1 In this issue of Angiology, Sprynger et al discuss the pros and cons of screening programs for abdominal aortic aneurysms (AAAs). 1 In their comprehensive review, they analyze the benefits and cost-effectiveness of these programs, which are however counterbalanced by the decrease in the prevalence of AAAs.
1 They attempt to answer 2 questions:
1. Does population-based ultrasound screening for AAAs achieve its objective? 2. Are AAA screening programs cost-effective?
In the present editorial, we consider some aspects of this topic.
Controversial Issues Regarding AAA Screening Programs
As the authors mention, 1 since January 1, 2007, provisions of the Screening Abdominal Aortic Aneurysm Very Efficiently Act in the United States have provided free, one-time, ultrasound AAA screening for qualified Medicare beneficiaries as part of their Welcome to Medicare examination. 2 Men who have smoked at least 100 cigarettes during their life, as well as both men and women with a family history of AAA qualify. 2 The UK Multicenter Aneurysm Screening Study (MASS) demonstrated that a one-time screening program for men leads to an incremental cost-effectiveness ratio of £7600 (roughly US$10 500) per quality-adjusted life-year gained at 10 years. 3 The long-term results of the MASS trial showed that 216 men need to be invited to screening to save 1 AAArelated death. 4 Other studies have also reported favorable cost-effectiveness of offering AAA screening to men. [5] [6] [7] Despite the lower prevalence of AAAs in women, screening women for AAAs may also be cost-effective because of the higher AAA rupture rate in women (and at smaller AAA diameters). 8 A single screening ultrasound for AAA in asymptomatic men aged >65 years has been shown to be cost-effective in the United Kingdom 9 and through Markov modeling. 10 In the United Kingdom, the cost per life-year saved with screening men >50 years was US$1173, which is less than for breast, cervical, and colorectal cancer screening programs.
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Despite the robust data on the benefit of AAA screening programs and their cost-effectiveness, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] there is evidence that such screening programs are underutilized. Analysis of the Medicare data revealed that <10% of eligible patients undergo screening with abdominal ultrasonography. 12, 13 Extrapolating screening benefits from 2007 to 2012 through 2025 showed that an additional 291 000 life-years can be saved by 2025 (or 131 life-years per 1000 persons screened) if screening rates increased from the 2007 to 2012 (<10%) to 80% by the end of 2018. 13 Despite this large body of evidence, others support that not only AAA screening programs are not beneficial but they also cause more harm than good.
14 According to this interpretation, "for every 10,000 people invited to screening, 46 men avoid dying from a ruptured AAA. But for every avoided death, 4 men are diagnosed with an AAA that would never have been detected or caused health problems in their lifetime without screening; they have been overdiagnosed, which causes substantial physical and psychological harms for many of them". 14(p.308) Admittedly, this interpretation may apply to specific categories of patients, such as those who are frail, who have several comorbidities, and/or who are at high risk for surgery. In a recent report, 112 patients with AAA turned down for elective repair were followed up for a minimum of 2 years. 15 Within 2 years, 64 (57.1%) of 112 had died. Of these, 30 of 64 had a recorded cause of death. Ruptured AAA was the cause of death in only 11 (36.7%) of 30 patients. 15 In other words, the majority of this group of frail patients with an AAA who were turned down for elective repair because of their comorbidities did not die of a ruptured AAA, but as a result of their comorbidities.
Another, independent study retrospectively analyzed 692 patients with AAA over a period of 20 years. 16 Overall, 214
deaths were recorded. Only 25 (11.7%) were AAA-related, whereas 171 (80.3%) patients died of other causes while under surveillance, having never required AAA surgery. 16 This report once again suggests that the majority of patients with AAA who die do not die of a ruptured AAA. 16 Therefore, screening such frail patients for an AAA is not likely to change their prognosis dramatically.
The current AAA diameter for intervention is 5.5 cm for men and 5.2 cm for women. 17 For such frail patients, it seems prudent to increase the threshold for intervention to 6.0 (or even to 6.5) cm. 18 Alternatively, high-risk, frail patients who are not likely to be offered elective AAA repair can be discharged. For these patients, AAA screening is neither necessary nor recommended. For average risk patients, however, AAA screening seems to have more advantages than disadvantages and this is why international guidelines strongly recommend AAA screening for specific patient subgroups (a strong recommendation for men or women 65 to 75 years old with a history of tobacco use and a weaker recommendation for firstdegree relatives of patients with an AAA). 17 
Benefits Associated With Screening Programs
Although detection of an AAA can be a psychological burden for some patients, 14 the early identification of patients with AAAs by screening programs has some important implications, namely:
Early Initiation of Primary Prevention Measures
According to the most recent guidelines on the management of AAAs, 17 it is strongly recommended that these patients receive best medical treatment, which includes smoking cessation, an antiplatelet agent, and a statin. Statins in particular are associated with several beneficial actions for patients with AAA, whether managed conservatively or undergoing open vascular or endovascular surgery.
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Planning Elective Repair Reduces the Incidence of Ruptured AAAs
Identification of patients with small AAAs via screening programs makes it possible to keep these patients under regular surveillance and plan an elective procedure when the AAA diameter exceeds the threshold for intervention. 17 Some of the patients presenting in the emergency departments of hospitals with a ruptured AAA were not aware of its presence before the time of rupture. A study from Denmark found a 74% reduction in the incidence of ruptured AAAs and a 68% reduction in cause-specific mortality by AAA screening programs. 22 
Improved Perioperative Mortality Rates
The early identification of patients with AAA via screening programs allows for timely/earlier management. The 5-year results of the previously mentioned study from Denmark verified a 75% reduction in the incidence of emergency operations for ruptured AAAs in the screening group compared with controls, a 67% reduction in AAA-specific mortality, and an estimated cost per prevented death from AAA of 16 050 Euros. 23 
Conclusions
Although the benefits and cost-effectiveness of AAA screening programs are an enduringly controversial topic, a growing body of evidence supports their use, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and the article by Sprynger et al 1 lends further support to this interpretation. A counterargument to those questioning the benefits and costeffectiveness of AAA screening programs 14 is the fact that every newborn child in the United Kingdom is routinely screened for several diseases, among others maple syrup urine disease (MSUD), isovaleric acidaemia, and homocystinuria. However, MSUD affects only 1 in every 185 000 infants worldwide, isovaleric acidaemia about 1 in every 250 000 people in the United States, and homocystinuria only 1 in every 200 000 to 335 000 people worldwide. Besides their much smaller prevalence, an ultrasound scan costs much less than the genetic tests required for the diagnosis of these rare conditions. 24 Abdominal aortic aneurysms screening programs are not just useful, they are essential tools to reduce AAA-related deaths.
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